Resistant Hypertension: Why Blood Pressure Won’t Drop

Resistant hypertension is blood pressure that stays above target despite the use of three different blood-pressure-lowering drugs at adequate doses, one of which should be a diuretic. The condition also includes people who need four or more medications to reach their goal. By current definitions, that target is below 130/80 mmHg, and roughly one in five treated hypertensive adults in the United States meets the criteria. The label sounds alarming, but the reality behind it is layered: some of these cases stem from genuine biological resistance to drugs, while a surprisingly large fraction turns out to be “pseudo-resistance” driven by missed pills, inaccurate readings, or treatable underlying conditions that nobody looked for.

What Counts as Resistant Hypertension

The American Heart Association defines resistant hypertension as above-goal blood pressure in someone already taking three antihypertensive drugs of different classes at maximum or maximally tolerated doses. The standard three-drug regimen typically includes a long-acting calcium channel blocker, a blocker of the renin-angiotensin system (such as an ACE inhibitor or an angiotensin receptor blocker), and a diuretic. Anyone whose pressure is controlled but who requires four or more medications to get there also qualifies.¹ Current guidelines set the threshold at 130/80 mmHg and explicitly require that two common mimics be ruled out before the diagnosis is applied: the white-coat effect, where blood pressure reads high in a clinical setting but is normal at home, and medication nonadherence.²

That second requirement is more important than it might sound. Without confirming that the patient is actually taking the prescribed drugs and that office readings reflect real out-of-office pressure, a clinician can easily mislabel someone as treatment-resistant when the problem is something else entirely.

How Common It Is

Estimates depend on how strictly you define it and which era’s blood-pressure targets you use. A large U.S. analysis using data from 2003 to 2008 found that about 9% of all adults with hypertension met criteria for resistant hypertension, which translated to roughly 13% of the drug-treated population.³ When the definition was updated to reflect the stricter 130/80 mmHg threshold, prevalence rose: about 20% of treated hypertensive U.S. adults qualified, amounting to roughly 10.3 million people.⁴

Globally, a meta-analysis pooling data from 3.2 million patients estimated that about 15% of treated hypertensive patients have apparent treatment-resistant hypertension, while the prevalence of “true” resistant hypertension, after pseudo-resistance has been excluded, sits closer to 10%.⁵ That gap between “apparent” and “true” matters enormously, because the patients who fall into the gap often don’t need more drugs; they need a different kind of help.

The Pseudo-Resistance Problem

Medication nonadherence is one of the biggest reasons people appear resistant to treatment when they may not be. A systematic review and meta-analysis of adherence among patients with apparent resistant hypertension found that roughly a third were not taking their medications as prescribed, with nonadherence rates ranging from about 3% to over 86% depending on how adherence was measured.⁶ The striking variability came down to detection method. Studies relying on patients’ self-reports or pharmacy refill data reported much lower nonadherence rates than studies using direct biochemical tests, such as detecting drug metabolites in blood or urine samples. When researchers actually measured drug levels, the numbers were often sobering.

This has real consequences. If a patient appears treatment-resistant but is actually missing doses, the usual next step of adding a fourth or fifth drug only increases pill burden, side-effect risk, and cost without addressing the actual problem. Clinicians increasingly advocate for objective adherence testing early in the workup, before anyone escalates therapy or considers invasive procedures.⁷

White-coat effect is the other major form of pseudo-resistance. Blood pressure measured in a doctor’s office can be substantially higher than what a person experiences during their normal daily life. Out-of-office monitoring, whether through ambulatory 24-hour devices or validated home monitors, is considered essential for distinguishing true resistance from white-coat hypertension.

Why the Body Resists Treatment

For patients who genuinely are resistant, the underlying biology usually involves one or more of three intertwined mechanisms: excess fluid and salt retention, overactivation of the hormonal system that regulates salt and water balance, and heightened sympathetic nervous system activity.

The kidneys play a central role. In many resistant patients, the normal process of excreting sodium in response to rising blood pressure is blunted. The body holds onto salt and water, expanding blood volume and driving pressure up. Activation of the renin-angiotensin-aldosterone system and increased renal sympathetic nerve activity reinforce that sodium retention, creating a cycle that standard drugs may not fully break.⁸ Excess sodium and fluid retention, overactivity of the renin-angiotensin-aldosterone system, and heightened sympathetic drive are consistently identified as the major physiological drivers.⁹

The sympathetic nervous system, which controls the “fight or flight” response, is measurably more active in people with resistant hypertension than in those whose blood pressure responds to standard treatment. Studies using the best available techniques for measuring nerve firing rates have confirmed this elevated sympathetic tone.¹⁰ What makes it stubborn is that multiple factors feed into that overactivation: insulin resistance, disrupted appetite hormones from excess fat tissue, endothelial dysfunction in blood vessel walls, and the intermittent oxygen drops caused by sleep apnea, among others.¹¹

Hidden Secondary Causes Worth Screening For

A significant portion of truly resistant cases have an identifiable secondary cause that, once treated, can dramatically improve blood pressure control. Three secondary causes show up repeatedly in the literature and deserve active screening.

Primary aldosteronism is probably the most underdiagnosed. The adrenal glands produce too much aldosterone, causing the kidneys to retain sodium and water while wasting potassium. Its prevalence climbs with hypertension severity, reaching up to about 29% in patients with resistant hypertension.¹² Beyond the salt-retention effect, aldosterone drives vascular remodeling, sympathetic overactivation, and insulin resistance, all of which worsen blood pressure independently. Finding and treating this condition, sometimes with targeted surgery, sometimes with aldosterone-blocking drugs, can transform a patient’s trajectory.

Obstructive sleep apnea is extremely common in people with resistant hypertension. The relationship may be bidirectional: fluid retention from poorly controlled blood pressure can shift fluid into the neck tissues at night, worsening airway obstruction, while the repeated oxygen drops from apnea episodes drive sympathetic activation and endothelial damage that further raise blood pressure. Obesity, a risk factor for both conditions, adds another link.¹³

Kidney disease and renal artery stenosis are additional culprits. A narrowed renal artery restricts blood flow to the kidney, which responds by activating the hormonal cascade that raises blood pressure. This can present as severe hypertension, worsening kidney function, or sudden fluid in the lungs.¹⁴ Chronic kidney disease itself impairs the kidney’s ability to excrete sodium, directly contributing to the volume overload that fuels resistance.

Certain medications and substances can also push blood pressure upward. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common offender because of how widely they are used; they promote salt and water retention and blunt the effect of many antihypertensive drugs.¹⁵ Oral contraceptives, certain antidepressants, stimulants, and even herbal supplements (like licorice root) can have similar effects. A thorough medication review is a basic but sometimes overlooked step in the workup.

Spironolactone as the Preferred Fourth Drug

When three drugs at full doses aren’t enough and secondary causes have been addressed, the best-supported next addition is spironolactone, an aldosterone-blocking drug. A large observational study found that adding spironolactone to a regimen of about three other drugs lowered blood pressure by an average of roughly 22/10 mmHg, a substantial drop that held across age groups, sexes, and patients with or without diabetes.¹⁶

The strongest evidence comes from the PATHWAY-2 trial, a randomized crossover study in which patients cycled through spironolactone, doxazosin (an alpha-blocker), bisoprolol (a beta-blocker), and placebo as add-on therapy. Spironolactone lowered home systolic blood pressure by about 9 mmHg more than placebo and about 4 mmHg more than either of the other active drugs.¹⁷ The ReHOT trial, which compared spironolactone head-to-head against clonidine (a centrally-acting drug), found that while the two had similar rates of overall blood pressure control, spironolactone produced a greater 24-hour blood-pressure reduction and had a simpler dosing schedule, leading the investigators to favor it.¹⁸

Spironolactone’s effectiveness makes sense given the underlying physiology. Even when a formal diagnosis of primary aldosteronism hasn’t been made, many resistant patients have some degree of excess aldosterone activity driving their volume overload. Blocking that pathway tackles one of the core mechanisms. The main limitation is that spironolactone can raise potassium levels and isn’t safe for people with significantly impaired kidney function or already-high potassium, so monitoring is required.

Sodium Restriction and Other Lifestyle Measures

Because salt and fluid retention are so central to resistant hypertension, cutting dietary sodium has a bigger impact in this population than it does in milder forms of hypertension. A randomized crossover trial in resistant hypertension patients found that switching from a high-salt diet to a low-salt diet dropped office systolic blood pressure by about 23 mmHg, a reduction comparable to adding another drug.¹⁹ Lab markers in the study confirmed that the improvement tracked with a reduction in blood volume. For people eating heavily processed or restaurant-heavy diets, the amount of sodium they are unknowingly consuming can be extreme, and changing this one habit can make a genuine difference.

Broader lifestyle interventions also help. Evidence from randomized trials shows that aerobic exercise, weight loss, and dietary changes can lower both clinic and ambulatory blood pressure in resistant hypertension, and multi-component programs combining these approaches also improve markers of cardiovascular risk beyond blood pressure itself.²⁰ These interventions are not substitutes for medication in truly resistant cases, but they meaningfully shrink the gap between where blood pressure sits and where it needs to be.

When You Take Your Medications May Matter

A disproportionate number of people with resistant hypertension have what’s known as a “non-dipping” blood pressure pattern: instead of the normal 10-15% drop in blood pressure during sleep, their nighttime pressure stays elevated or even rises. This pattern is associated with a worse cardiovascular outlook.²¹

Chronotherapy, the strategy of shifting one or more antihypertensive medications from morning to bedtime, has shown promise for addressing this. One study of resistant hypertension patients found that simply moving one drug to a bedtime dose lowered ambulatory blood pressure by about 9/6 mmHg, with the reduction concentrated overnight. Before the switch, only 16% of patients showed a normal dipping pattern; afterward, 57% did.²² Similar results have been reported in non-dipper patients with refractory hypertension, where evening dosing improved blood pressure control.²³

The idea is straightforward: if the drugs are wearing off by nighttime when pressure should be at its lowest, shifting the dose timing gives better coverage during those vulnerable hours. However, more recent and larger trials have raised questions about whether bedtime dosing reliably translates into long-term cardiovascular benefit, and the approach remains an area of active debate. For patients whose ambulatory monitoring reveals a clear non-dipping pattern, it’s a reasonable conversation to have with a prescriber.

Newer Drug and Device Therapies

Two newer approaches are expanding the options for patients who remain uncontrolled despite optimized medication regimens.

Aprocitentan, a dual endothelin receptor antagonist, blocks the effects of endothelin, a potent blood-vessel constricting substance. In the phase 3 PRECISION trial, aprocitentan at 12.5 mg reduced office systolic blood pressure by about 15 mmHg at four weeks, roughly 4 mmHg more than placebo, with sustained effects through 40 weeks. The 24-hour ambulatory blood pressure reductions were even more pronounced, at 4-6 mmHg greater than placebo.²⁴ While a 4 mmHg advantage over placebo sounds modest, in a population where every additional mmHg reduction is hard-won, it represents a meaningful clinical gain. Aprocitentan targets a biological pathway that traditional antihypertensives don’t address, which is why it works on top of existing regimens.²⁵

Renal denervation is a catheter-based procedure that disrupts the sympathetic nerves running along the renal arteries. Since sympathetic overactivation is a core driver of resistant hypertension, the rationale is direct. The field hit a setback in 2014 when a major sham-controlled trial failed to show a benefit, but newer technologies using multipolar radiofrequency catheters and ultrasound-based ablation that penetrates tissue more effectively have revived the approach. Evidence from recent sham-controlled trials now supports a blood-pressure-lowering effect that appears durable.²⁶ Earlier randomized data from the Symplicity HTN-2 trial had demonstrated that catheter-based renal denervation could safely and substantially reduce blood pressure in treatment-resistant patients.²⁷ Renal denervation is not a first-line option and is typically reserved for patients who have exhausted pharmacological strategies, but it has moved from experimental curiosity to a credible tool in the arsenal.

Why the Stakes Are Higher Than Ordinary Hypertension

Resistant hypertension is not just harder to treat; it carries substantially worse health outcomes than hypertension that responds to standard therapy. A large registry study found that people with apparent resistant hypertension faced roughly 1.8 times the risk of death from cardiac causes, 2.3 times the risk of kidney failure, about 1.5 times the risk of brain hemorrhage, and 1.4 times the risk of heart failure compared with treated hypertensive patients whose blood pressure was controlled.²⁸

Data from the landmark ALLHAT trial showed a similar pattern: participants with resistant hypertension had about a 44% higher risk of coronary heart disease, a 57% higher risk of stroke, an 88% higher risk of heart failure, and roughly double the risk of end-stage kidney disease compared with those whose hypertension was not resistant.²⁹ Even among resistant patients, those whose blood pressure remains uncontrolled fare worse than those who achieve control on four or more drugs, particularly for kidney outcomes and stroke.³⁰ The message is clear: reaching target blood pressure, even if it takes multiple medications and lifestyle overhauls, translates into meaningful risk reduction.

The Genetics Angle and Specialized Care

There is growing interest in whether genetic variation helps explain why some people’s blood pressure simply refuses to budge. Differences in genes governing the renin-angiotensin-aldosterone system, sodium transport, and drug metabolism could affect how well a given person responds to specific antihypertensive classes and may contribute to the resistant hypertension phenotype.³¹ This field is still in its early stages and hasn’t yet produced clinically actionable tests for most patients. But it points toward a future in which drug selection might be guided partly by a patient’s genetic profile rather than purely by trial and error.

Managing resistant hypertension well requires more than simply adding pills. It calls for systematic detective work: confirming adherence, ruling out secondary causes, optimizing diuretic dosing, controlling sodium intake, screening for sleep apnea, and considering when to time medications. Specialized hypertension clinics that bundle these evaluations are increasingly recognized as valuable, though the cost of providing that level of coordinated care is significant.³² For patients stuck at above-goal readings despite what feels like maximal effort, a referral to such a clinic, or at minimum to a hypertension specialist, is often the step that finally breaks through the plateau.